Cover Image
市場調查報告書

小細胞肺癌:開發平台分析

Small-Cell Lung Cancer - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 229729
出版日期 內容資訊 英文 645 Pages
訂單完成後即時交付
價格
Back to Top
小細胞肺癌:開發平台分析 Small-Cell Lung Cancer - Pipeline Review, H1 2016
出版日期: 2016年05月25日 內容資訊: 英文 645 Pages
簡介

所謂小細胞肺癌(SCLC)是急速惡化的肺癌類型。比非小細胞癌惡化更快。是肺癌中惡化最快的型態。一般會在胸部中心的呼吸道(支氣管)發病。在很多情況下會迅速轉移到腦部、肝臟、骨骼及身體其他部位。常見的症狀有血痰、胸部疼痛、咳嗽、食慾不振、體重減少、喘鳴等。治療方法包含外科手術、放射線治療、化療等。

本報告提供小細胞肺癌的治療藥的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,以及最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

小細胞肺癌概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

  • 4SC AG
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • AbbVie Inc.
  • Alchemia Limited
  • Amgen Inc.
  • Andarix Pharmaceuticals, Inc.
  • Aposense Ltd.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • AVEO Pharmaceuticals, Inc.
  • Bayer AG
  • BeiGene, Ltd.
  • BIND Therapeutics, Inc.
  • BioLineRx, Ltd.
  • Bionomics Limited
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • CellAct Pharma GmbH
  • Cellceutix Corporation
  • Cerulean Pharma, Inc.
  • Cornerstone Pharmaceuticals, Inc.
  • Critical Outcome Technologies Inc.
  • CytRx Corporation
  • Double Bond Pharmaceutical International AB 另外

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7991IDB

Summary

Global Markets Direct's, 'Small-Cell Lung Cancer - Pipeline Review, H1 2016', provides an overview of the Small-Cell Lung Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Small-Cell Lung Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Small-Cell Lung Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer
  • The report reviews pipeline therapeutics for Small-Cell Lung Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Small-Cell Lung Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Small-Cell Lung Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Small-Cell Lung Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Small-Cell Lung Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Small-Cell Lung Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Small-Cell Lung Cancer Overview
  • Therapeutics Development
  • Small-Cell Lung Cancer - Therapeutics under Development by Companies
  • Small-Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes
  • Small-Cell Lung Cancer - Pipeline Products Glance
  • Small-Cell Lung Cancer - Products under Development by Companies
  • Small-Cell Lung Cancer - Products under Investigation by Universities/Institutes
  • Small-Cell Lung Cancer - Companies Involved in Therapeutics Development
  • Small-Cell Lung Cancer - Therapeutics Assessment
  • Drug Profiles
  • Small-Cell Lung Cancer - Recent Pipeline Updates
  • Small-Cell Lung Cancer - Dormant Projects
  • Small-Cell Lung Cancer - Discontinued Products
  • Small-Cell Lung Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Small-Cell Lung Cancer, H1 2016
  • Number of Products under Development for Small-Cell Lung Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Small-Cell Lung Cancer - Pipeline by 4SC AG, H1 2016
  • Small-Cell Lung Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2016
  • Small-Cell Lung Cancer - Pipeline by AbbVie Inc., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Alchemia Limited, H1 2016
  • Small-Cell Lung Cancer - Pipeline by Amgen Inc., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Andarix Pharmaceuticals, Inc., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Aposense Ltd., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Astellas Pharma Inc., H1 2016
  • Small-Cell Lung Cancer - Pipeline by AstraZeneca Plc, H1 2016
  • Small-Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Bayer AG, H1 2016
  • Small-Cell Lung Cancer - Pipeline by BeiGene, Ltd., H1 2016
  • Small-Cell Lung Cancer - Pipeline by BIND Therapeutics, Inc., H1 2016
  • Small-Cell Lung Cancer - Pipeline by BioLineRx, Ltd., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Bionomics Limited, H1 2016
  • Small-Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Small-Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Small-Cell Lung Cancer - Pipeline by CellAct Pharma GmbH, H1 2016
  • Small-Cell Lung Cancer - Pipeline by Cellceutix Corporation, H1 2016
  • Small-Cell Lung Cancer - Pipeline by Cerulean Pharma, Inc., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2016
  • Small-Cell Lung Cancer - Pipeline by CytRx Corporation, H1 2016
  • Small-Cell Lung Cancer - Pipeline by Double Bond Pharmaceutical International AB, H1 2016
  • Small-Cell Lung Cancer - Pipeline by Eli Lilly and Company, H1 2016
  • Small-Cell Lung Cancer - Pipeline by Exelixis, Inc., H1 2016
  • Small-Cell Lung Cancer - Pipeline by G1 Therapeutics, Inc., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Genzyme Corporation, H1 2016
  • Small-Cell Lung Cancer - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Small-Cell Lung Cancer - Pipeline by Horizon Pharma Plc, H1 2016
  • Small-Cell Lung Cancer - Pipeline by Hutchison MediPharma Limited, H1 2016
  • Small-Cell Lung Cancer - Pipeline by Immunomedics, Inc., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Incyte Corporation, H1 2016
  • Small-Cell Lung Cancer - Pipeline by Ipsen S.A., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Johnson & Johnson, H1 2016
  • Small-Cell Lung Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Lindis Biotech GmbH, H1 2016
  • Small-Cell Lung Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H1 2016
  • Small-Cell Lung Cancer - Pipeline by MedImmune, LLC, H1 2016
  • Small-Cell Lung Cancer - Pipeline by Medivation, Inc., H1 2016
  • Small-Cell Lung Cancer - Pipeline by MEI Pharma, Inc., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Merck & Co., Inc., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Mirna Therapeutics, Inc., H1 2016
  • Small-Cell Lung Cancer - Pipeline by MolMed S.p.A., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Mologen AG, H1 2016
  • Small-Cell Lung Cancer - Pipeline by NanoSmart Pharmaceuticals, Inc., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Nektar Therapeutics, H1 2016
  • Small-Cell Lung Cancer - Pipeline by Nippon Kayaku Co., Ltd., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Novartis AG, H1 2016
  • Small-Cell Lung Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2016
  • Small-Cell Lung Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Onxeo SA, H1 2016
  • Small-Cell Lung Cancer - Pipeline by Oxford BioTherapeutics Ltd, H1 2016
  • Small-Cell Lung Cancer - Pipeline by Pfizer Inc., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Pharma Mar, S.A., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2016
  • Small-Cell Lung Cancer - Pipeline by SciTech Development, LLC , H1 2016
  • Small-Cell Lung Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Syros Pharmaceuticals, Inc., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Tarveda Therapeutics, Inc., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Tesaro, Inc., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016
  • Small-Cell Lung Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016
  • Small-Cell Lung Cancer - Pipeline by ViiV Healthcare Limited, H1 2016
  • Small-Cell Lung Cancer - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Small-Cell Lung Cancer Therapeutics - Recent Pipeline Updates, H1 2016
  • Small-Cell Lung Cancer - Dormant Projects, H1 2016
  • Small-Cell Lung Cancer - Dormant Projects (Contd..1), H1 2016
  • Small-Cell Lung Cancer - Dormant Projects (Contd..2), H1 2016
  • Small-Cell Lung Cancer - Dormant Projects (Contd..3), H1 2016
  • Small-Cell Lung Cancer - Dormant Projects (Contd..4), H1 2016
  • Small-Cell Lung Cancer - Dormant Projects (Contd..5), H1 2016
  • Small-Cell Lung Cancer - Dormant Projects (Contd..6), H1 2016
  • Small-Cell Lung Cancer - Discontinued Products, H1 2016
  • Small-Cell Lung Cancer - Discontinued Products (Contd..1), H1 2016

List of Figures

  • Number of Products under Development for Small-Cell Lung Cancer, H1 2016
  • Number of Products under Development for Small-Cell Lung Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top